Lung cancer is the most important malignancy-related death worldwide, causing more than 150,000 deaths in the United States alone every year [1]. Two broad categories exist - small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), with approximately 85% of new cases being NSCLC [2] [3] [4]. Squamous cell carcinoma of the lung (estimated to cause 400,000 deaths worldwide every year) comprises approximately 30% of all NSCLC cases [2] [5] [6] [7]. Similarly to other subtypes, tobacco smoking remains the single most important risk factor for its development, while exposure to radon gas and asbestos are well-known risk factors as well [2] [5] [6] [7]. The clinical presentation of lung cancer is highly variable. The diagnosis is made incidentally in a significant number of patients, as many are asymptomatic when lung cancer is detected [4] [8]. Conversely, the progression of the tumor and several other factors (eg. location) may lead to symptoms such as dyspnea, chest pain, hemoptysis, weight loss, fatigue, and anorexia [3] [4] [8] [9]. Numerous complications are documented, including pleural effusions, thromboembolic disease, together with several paraneoplastic syndromes that have been described [4] [8] [9]. Additionally, metastatic spread to various sites can produce characteristic symptoms - localized pain and fractures are seen with skeletal metastases; headaches, nausea, vomiting, and mental changes are main signs of cranial spread, whereas lymphadenopathy, hepatomegaly, and subcutaneous nodules are other notable findings [8]. Given the limited choices of therapy for squamous cell carcinoma of the lung the prognosis remains poor, particularly in the case of metastatic spread [7].

The diagnosis of squamous cell carcinoma of the lung rests on a comprehensive clinical, imaging, and histopathological workup. Firstly, the physician should conduct a detailed patient history (during which the course of symptoms and their severity should be assessed) and perform a meticulous physical examination [8]. Because of the insidious nature of lung cancer in general (including squamous cell carcinoma of the lung), this diagnosis should be considered in all cases who present with undisclosed respiratory and constitutional complaints. Plain radiography of the chest is the first imaging study the needs to be employed, which may show single or multiple masses, hilar enlargement, atelectasis, and many other findings that suggest a malignant process, but some patients have a normal X-ray if smaller tumors are present or if their location renders them poorly visible [4] [9]. For this reason, computed tomography (CT) or positron emission tomography (PET) are recommended [4] [9] [10]. To discriminate between lung tumors and confirm the diagnosis of squamous cell carcinoma of the lung, it is necessary to perform a biopsy of the lesion. A CT-guided percutaneous biopsy or a flexible bronchoscopy with subsequent histopathological examination and immunohistochemistry can be done [9] [10] [11]. Additional methods that may be implemented are conventional bronchoscopy, mediastinoscopy, and aspiration cytology of pleural fluid, whereas electromagnetic navigation (EMN) bronchoscopy and radial endobronchial ultrasound (R-EBUS)-guided lung biopsy are novel techniques that show promising results [4] [9] [11].

Treatment for squamous cell carcinoma of the lung depends on the stage of the disease and the overall health of the patient. Options may include surgery, radiation therapy, chemotherapy, targeted therapy, or a combination of these. Surgery is often considered for early-stage cancers and involves removing the tumor and surrounding tissue. Radiation therapy uses high-energy rays to kill cancer cells, while chemotherapy uses drugs to destroy them. Targeted therapies are newer treatments that specifically target cancer cell mechanisms. The choice of treatment is tailored to each patient based on the specific characteristics of their cancer.

The prognosis for squamous cell carcinoma of the lung varies depending on the stage at diagnosis and the patient's overall health. Early-stage cancers that are localized to the lung have a better prognosis and may be curable with surgery. However, if the cancer has spread to other parts of the body, the prognosis is generally poorer. Advances in treatment have improved outcomes for many patients, but lung cancer remains a serious disease with significant mortality.

The primary cause of squamous cell carcinoma of the lung is smoking. Tobacco smoke contains numerous carcinogens that damage the DNA in lung cells, leading to cancer. Other risk factors include exposure to secondhand smoke, occupational exposure to certain chemicals (such as asbestos and radon), and a history of lung diseases like chronic obstructive pulmonary disease (COPD). Genetic factors may also play a role in the development of lung cancer.

Squamous cell carcinoma of the lung is one of the most common types of lung cancer, accounting for about 25-30% of all lung cancer cases. It is more prevalent in men than women, largely due to higher smoking rates among men. The incidence of SCC has been declining in recent years, reflecting a decrease in smoking rates. However, it remains a significant public health concern worldwide.

Squamous cell carcinoma of the lung develops when the squamous cells lining the airways undergo genetic mutations that cause them to grow uncontrollably. These mutations can be triggered by carcinogens in tobacco smoke or other environmental factors. As the cancer cells multiply, they form a mass or tumor that can invade nearby tissues and spread to other parts of the body (metastasis). The central location of SCC in the lungs often leads to symptoms related to airway obstruction.

The most effective way to prevent squamous cell carcinoma of the lung is to avoid smoking and exposure to tobacco smoke. Quitting smoking significantly reduces the risk of developing lung cancer. Additionally, reducing exposure to known carcinogens, such as asbestos and radon, can help lower the risk. Regular health check-ups and screenings for high-risk individuals may aid in early detection and improve outcomes.

Squamous cell carcinoma of the lung is a common type of lung cancer strongly linked to smoking. It presents with symptoms like persistent cough and chest pain and is diagnosed through imaging and biopsy. Treatment options include surgery, radiation, and chemotherapy, with the choice depending on the cancer stage and patient health. Prevention focuses on smoking cessation and reducing exposure to carcinogens.

If you or someone you know is experiencing symptoms such as a persistent cough, chest pain, or coughing up blood, it is important to seek medical evaluation. Early detection of lung cancer can significantly improve treatment outcomes. Quitting smoking is the most effective way to reduce the risk of developing lung cancer. If you are a smoker, consider seeking support to quit, as this can greatly benefit your overall health and reduce your cancer risk.

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7-30.
2. Heist RS, Mino-Kenudson M, Sequist LV, et al. FGFR1 amplification in squamous cell carcinoma of the lung. J Thorac Oncol. 2012;7(12):1775-1780.
3. Ettinger DS, Akerley W, Bepler G, et al. Non-small cell lung cancer. J Natl Compr Canc Netw. 2010;8(7):740-801.
4. Porter RS, Kaplan JL. Merck Manual of Diagnosis and Therapy. 19th Edition. Merck Sharp & Dohme Corp. Whitehouse Station, N.J; 2011.
5. Derman BA, Mileham KF, Bonomi PD, Batus M, Fidler MJ. Treatment of advanced squamous cell carcinoma of the lung: a review. Transl Lung Cancer Res. 2015;4(5):524-532.
6. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489(7417):519-525.
7. Rooney M, Devarakonda S, Govindan R. Genomics of Squamous Cell Lung Cancer. Oncologist. 2013;18(6):707-716.
8. Latimer KM, Mott TF. Lung cancer: diagnosis, treatment principles, and screening. Am Fam Physician. 2015;91(4):250-256.
9. Simoff MJ, Lally B, Slade MG, et al. Symptom management in patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e455S-497S.
10. Dietel M, Bubendorf L, Dingemans A-MC, et al. Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group. Thorax. 2016;71(2):177-184.
11. Rivera MP, Mehta AC, Wahidi MM. Establishing the diagnosis of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e142S-165S.